skip to main content

Ultrasound-Guided Treatment — SCE Rheumatology MCQ

Instant feedback + full explanation. One question, done properly.

HardMusculoskeletal ImagingUltrasound-Guided TreatmentSCE Rheumatology

A 55-year-old woman with established rheumatoid arthritis has maintained low disease activity for 6 months on a stable, optimised dose of methotrexate. She reports recent right wrist pain, but examination shows tenderness without definite swelling, CRP is normal and her DAS28-ESR is 2.8. Ultrasound arranged because of the discordant symptoms shows marked synovial hypertrophy of the wrist with grade 3 power Doppler signal. There are no features to suggest infection or crystal arthropathy. Which is the most appropriate interpretation of the ultrasound findings for her systemic DMARD strategy?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: B — Do not escalate systemic DMARD therapy solely to abolish the power Doppler signal; integrate the finding with clinical assessment at treat-to-target review

Explanation lettering: D = shown as A · E = shown as C · A = shown as D · C = shown as E

B is correct. Power Doppler synovitis can reveal inflammation missed on examination and is associated at group level with flare and structural progression, so the finding should inform clinical review — particularly here, where symptoms and composite scores are discordant. However, ultrasound activity is not a validated independent treatment target: the ARCTIC and TaSER strategy trials showed that escalating therapy to achieve imaging remission intensified treatment without improving clinical, functional or radiographic outcomes over clinical treat-to-target, and NICE NG100 states that RCT evidence does not support routine ultrasound monitoring, reserving it for inconclusive or discordant presentations. A and C wrongly make Doppler signal alone a mandatory escalation trigger; D overstates prognosis — grade 3 signal raises risk but does not make progression inevitable or mandate an immediate biologic; E is wrong because a low DAS28 neither justifies de-escalation nor renders a clinically relevant discordant imaging finding irrelevant.

Reference: NICE. Rheumatoid arthritis in adults: management (NG100), Recommendations for research — ultrasound to monitor disease. Published 2018, updated 2020. https://www.nice.org.uk/guidance/ng100/chapter/recommendations-for-research